|Articles|July 1, 2004
CONTROL, SURVIVAL IMPROVE
ImClone Systems Inc. and Bristol-Myers Squibb Co. report that the combination of Erbitux (cetuximab) injection and high-dose radiation yielded locoregional control and improved survival rate for patients with locally advanced squamous cell carcinoma of the head and neck.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement














